Amarantus BioScience Holdings, Inc. (AMBS)

0.0001 0.0000 (0.00%) At close: 03:20PM EDT

Amarantus BioScience Holdings, Inc.

45 Wall Street
Suite 920
New York, NY 10005
United States
650-862-5391
https://www.amarantus.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Gerald E. Commissiong	CEO, President & Director	N/A	N/A	1983
Dr. John Wesley Commissiong	Chief Scientific Officer, Director & Member of Scientific Advisory Board	N/A	N/A	1945
Mr. Robert Lewis Harris	Compliance Officer & Director	N/A	N/A	1944
Aimee Boutcher	Director of Investor Relations	N/A	N/A	N/A
Dr. Ravi Kiron	Senior Vice President of Business Development	N/A	N/A	1960
Dr. Brian E. Harvey	Chief Regulatory Advisor & Member of Board of Advisors	N/A	N/A	N/A
Dr. Owen Garrick	Corporate Advisor	N/A	N/A	N/A

Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

Corporate Governance

Amarantus BioScience Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.